Is platinib treatment effective?

Pralsetinib is a highly selective RET inhibitor, mainly used to treat non-small cell lung cancer (NSCLC) and thyroid cancer related to RET gene fusion mutations. According to existing clinical research results, platinib has shown good therapeutic effects in this type of patients. Especially in RET fusion-positive patients with limited treatment options and poor prognosis in the past, platinib provides new hope for disease control and remission.

In the field of non-small cell lung cancer, the effectiveness of platinib is particularly outstanding. According to ARROW clinical trial data, RETfusion-positive NSCs treated with platinib The overall response rate (ORR) of LCpatients exceeds 60%, and some patients even achieve complete remission. Whether it is patients who have received previous treatment or patients who are new to treatment, platinib has shown considerable efficacy, and at the same time, it is accompanied by prolonged disease progression time (PFS), which significantly improves the quality of life of patients.

Platinib also shows good efficacy in the treatment ofRET mutated thyroid cancer. Research shows that platinib can bring significant tumor shrinkage to patients with either differentiated thyroid cancer (DTC) or medullary thyroid cancer (MTC). After using platinib, many patients have significantly reduced tumor burden and prolonged disease stabilization time, making treatment more controllable and providing patients with more treatment opportunities.

Overall, the effect of platinib in treating RET fusion or mutation-related tumors is positive. Although some patients may experience common side effects such as high blood pressure, constipation, and fatigue, most side effects can be controlled through dose adjustment or supportive care. As more research advances, platinib is expected to be used in a wider range of RET-related tumor treatment fields in the future, further benefiting more patients.

Reference materials:https://gavreto.com/